GO:0032911 negative regulation of transforming growth factor beta1 production: Cytokine Control Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032911 describes any biological process that stops, prevents, or reduces the production of transforming growth factor-beta1 (TGF-beta1), a master cytokine controlling fibrosis, immunity, and cell growth.
• Loss of negative regulation of TGF-beta1 production sustains chronic inflammation, as seen in gut inflammation where failure of this process maintains NF-kappaB activation.
• Key negative regulators include Smad7, which is induced by the GPR81-CREB pathway and alleviates liver fibrosis by suppressing TGF-beta1 signaling.
• TGF-beta1 production is also controlled post-transcriptionally; for example, miR-204-5p inhibits TGF-beta1-induced proliferation and extracellular matrix production in airway smooth muscle cells.
• Dysregulation of this process contributes to cancer metastasis, asthma airway remodeling, and aldosterone-related hypertension.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect the causal roles of genes that negatively regulate TGF-beta1 production.
Description
Transforming growth factor-beta1 (TGF-beta1) is a pleiotropic cytokine that governs cell proliferation, differentiation, immune responses, and extracellular matrix deposition. Because excessive or sustained TGF-beta1 activity drives fibrosis, cancer progression, and chronic inflammatory diseases, its production must be tightly controlled. GO:0032911, negative regulation of transforming growth factor beta1 production, captures the biological processes that stop, prevent, or reduce the frequency, rate, or extent of TGF-beta1 production. This term is critical for researchers studying cytokine networks, tissue homeostasis, and disease pathogenesis. The importance of this regulatory process is underscored by studies showing that a failure of TGF-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation, linking defective cytokine control to chronic inflammatory pathology. Similarly, in liver fibrosis, deletion of GPR81 activates the CREB/Smad7 pathway, which in turn negatively regulates TGF-beta1 signaling and alleviates fibrosis in mice. These examples illustrate that understanding how TGF-beta1 production is restrained offers therapeutic opportunities across fibrosis, cancer, and inflammatory diseases. This article integrates authoritative QuickGO annotation data with verified PubMed literature to provide a research-grade overview of GO:0032911, its mechanisms, key genes, disease relevance, and experimental strategies for investigation.
negative regulation of transforming growth factor beta1 production At A Glance
| GO ID | GO:0032911 |
|---|---|
| GO term | negative regulation of transforming growth factor beta1 production |
| Ontology | biological_process |
| Synonym | down regulation of transforming growth factor-beta1 production; down-regulation of transforming growth factor-beta1 production; downregulation of transforming growth factor-beta1 production; inhibition of transforming growth factor-beta1 production; negative regulation of TGF-B1 production; negative regulation of TGFB1 production; negative regulation of transforming growth factor-beta1 production |
| Major function | Stops, prevents, or reduces the production of TGF-beta1, a key cytokine in fibrosis, immunity, and cell growth. |
| Related processes | Regulation of TGF-beta1 signaling, Smad7 induction, CREB pathway, NF-kappaB activation, extracellular matrix production. |
| Disease relevance | Gut inflammation, liver fibrosis, asthma airway remodeling, cancer metastasis, aldosterone-related hypertension. |
| Key regulators | Smad7, GPR81, miR-204-5p, Six1, Metrnl/IL-41, cyclooxygenase-2. |
What Is GO:0032911?
GO:0032911 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of production of transforming growth factor-beta1. In other words, it encompasses all molecular and cellular events that negatively regulate the synthesis, processing, or secretion of TGF-beta1, thereby limiting the amount of active cytokine available to bind its receptors and initiate signaling. This regulation can occur at transcriptional, post-transcriptional, translational, or post-translational levels and may involve cytokines, growth factors, microRNAs, or intracellular signaling cascades that ultimately suppress TGF-beta1 production.
Why Is negative regulation of transforming growth factor beta1 production Important in Cell Biology?
GO:0032911 is important because TGF-beta1 is a central mediator of fibrosis, immunosuppression, and tumor progression, and its production must be tightly controlled to maintain tissue homeostasis. When negative regulation fails, sustained TGF-beta1 production contributes to chronic inflammatory diseases such as inflammatory bowel disease, where a failure of TGF-beta1 negative regulation maintains NF-kappaB activation. In liver fibrosis, activation of the GPR81-CREB-Smad7 axis negatively regulates TGF-beta1 signaling and alleviates fibrosis, highlighting a protective role for this process. In asthma, miR-204-5p inhibits TGF-beta1-induced proliferation and extracellular matrix production in airway smooth muscle cells, demonstrating that negative regulation of TGF-beta1 responses can limit airway remodeling. Thus, understanding GO:0032911 provides mechanistic insights and therapeutic targets for a wide range of human diseases.
• Controls fibrosis: negative regulation of TGF-beta1 production prevents excessive extracellular matrix deposition in liver, lung, and kidney.
• Limits chronic inflammation: failure of this process sustains NF-kappaB activation in gut inflammation.
• Modulates cancer progression: TGF-beta1 promotes metastasis, and its negative regulation may suppress tumor spread.
• Regulates airway remodeling in asthma: miR-204-5p negatively regulates TGF-beta1-induced effects in airway smooth muscle cells.
• Influences aldosterone production and hypertension: TGF-beta1 interacts with aldosterone pathways.
• Affects immune cell function: macrophage extracellular traps are inhibited by Metrnl/IL-41, which suppresses airway remodeling via TGF-beta1-related mechanisms.
• Provides therapeutic targets: Smad7 induction via GPR81 activation alleviates liver fibrosis.
• Guides CRISPR modeling: knockout of negative regulators can reveal causal roles in disease.
• Links to nitric oxide control: TGF-beta1 regulates nitric oxide production, and its negative regulation may impact vascular biology.
• Informs biomarker development: circulating TGF-beta1 levels reflect the balance of production and negative regulation.
What Happens During negative regulation of transforming growth factor beta1 production?
Initiation of negative regulatory signals
In simple terms: A cell receives a signal that tells it to make less TGF-beta1.
Negative regulation of TGF-beta1 production begins when extracellular or intracellular cues activate pathways that suppress TGF-beta1 gene expression or protein synthesis. For example, activation of GPR81 by its ligand induces the CREB/Smad7 pathway, which negatively regulates TGF-beta1 signaling and alleviates liver fibrosis in mice. Similarly, in gut inflammation, a failure of TGF-beta1 negative regulation maintains sustained NF-kappaB activation, indicating that negative regulatory signals are required to restrain TGF-beta1 production.
Transcriptional and post-transcriptional suppression
In simple terms: The cell reduces the amount of instructions for making TGF-beta1.
Once negative regulatory signals are initiated, they can act at transcriptional or post-transcriptional levels. MicroRNAs such as miR-204-5p inhibit TGF-beta1-induced proliferation and extracellular matrix production in airway smooth muscle cells by regulating Six1, demonstrating post-transcriptional control of TGF-beta1 responses. Additionally, regulation of TGF-beta-dependent cyclooxygenase-2 expression in fibroblasts involves complex feedback mechanisms that can influence TGF-beta1 production.
Protein-level control and feedback
In simple terms: The cell adjusts the amount of active TGF-beta1 protein available.
Negative regulation can also occur at the level of protein processing, secretion, or stability. For instance, TGF-beta1 controls nitric oxide production, and mechanistic insights into this relationship reveal potential feedback loops that may limit TGF-beta1 bioavailability. In asthma, inhibition of macrophage extracellular traps by Metrnl/IL-41 suppresses airway remodeling, a process that involves TGF-beta1-dependent mechanisms.
Integration with signaling networks
In simple terms: The negative regulation is connected to other cellular decisions.
Negative regulation of TGF-beta1 production is integrated with broader signaling networks, including NF-kappaB and Smad pathways. In gut inflammation, the failure of TGF-beta1 negative regulation sustains NF-kappaB activation, linking cytokine control to inflammatory signaling. In liver fibrosis, the GPR81-CREB-Smad7 axis connects metabolic sensing to TGF-beta1 suppression. These integration points determine whether cells proliferate, differentiate, or deposit extracellular matrix.
Outcomes: reduced TGF-beta1 availability
In simple terms: The final result is less TGF-beta1, which changes how cells behave.
The ultimate outcome of GO:0032911 is a reduction in the frequency, rate, or extent of TGF-beta1 production. This can limit TGF-beta1-driven processes such as fibrosis, metastasis, and airway remodeling. For example, deletion of GPR81 activates CREB/Smad7 and alleviates liver fibrosis, showing that enhancing negative regulation can be therapeutic. In cancer, TGF-beta1 facilitates gallbladder carcinoma metastasis, so negative regulation may oppose metastatic spread.
Key Genes Involved in GO:0032911 negative regulation of transforming growth factor beta1 production
The following genes and proteins are experimentally implicated in the negative regulation of TGF-beta1 production or in related regulatory pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Smad7 | Inhibitory Smad that negatively regulates TGF-beta1 signaling and production | Induced by GPR81-CREB pathway; alleviates liver fibrosis in mice |
| GPR81 | G-protein coupled receptor that activates CREB/Smad7 to suppress TGF-beta1 | Deletion alleviates liver fibrosis; potential drug target |
| CREB | Transcription factor downstream of GPR81 that induces Smad7 | Mediates negative regulation of TGF-beta1 in liver |
| miR-204-5p | MicroRNA that inhibits TGF-beta1-induced proliferation and ECM production | Regulates Six1 in airway smooth muscle cells in asthma |
| Six1 | Transcription factor targeted by miR-204-5p in TGF-beta1 signaling | Involved in airway smooth muscle remodeling |
| Metrnl/IL-41 | Cytokine that inhibits macrophage extracellular traps and suppresses airway remodeling | Linked to TGF-beta1-related asthma pathology |
| NF-kappaB | Inflammatory transcription factor sustained when TGF-beta1 negative regulation fails | Key mediator in gut inflammation |
| COX-2 | Cyclooxygenase-2 regulated by TGF-beta-dependent mechanisms in fibroblasts | Feedback regulation of TGF-beta1 responses |
| Nitric oxide | Signaling molecule controlled by TGF-beta1 | Mechanistic insights into TGF-beta1 biology |
| Aldosterone | Hormone that interacts with TGF-beta1 pathways | Relevant to hypertension and renal disease |
| FOXA1 | Transcription factor regulated by TGF-beta1 via m6A modification | Promotes gallbladder carcinoma metastasis |
| TGF-beta1 | The cytokine whose production is negatively regulated | Central mediator of fibrosis, immunity, and cancer |
| TGF-beta receptor | Receptor that mediates TGF-beta1 signaling | Upstream of Smad activation |
| Smad2/3 | Receptor-regulated Smads that transduce TGF-beta1 signals | Opposed by Smad7 |
| CREB target genes | Genes induced by CREB that may include Smad7 | Mediate negative feedback |
| m6A machinery | RNA modification complex affecting FOXA1 translation | Modulates TGF-beta1-driven metastasis |
How Is negative regulation of transforming growth factor beta1 production Regulated?
The negative regulation of TGF-beta1 production is itself controlled by multiple signaling pathways. The GPR81-CREB-Smad7 axis is a key mechanism: activation of GPR81 induces CREB, which upregulates Smad7, an inhibitory Smad that suppresses TGF-beta1 signaling and alleviates liver fibrosis. In gut inflammation, failure of TGF-beta1 negative regulation sustains NF-kappaB activation, indicating that inflammatory signaling can override negative regulatory checkpoints. MicroRNAs such as miR-204-5p provide post-transcriptional control by inhibiting TGF-beta1-induced proliferation and extracellular matrix production in airway smooth muscle cells. Additionally, TGF-beta1 itself regulates cyclooxygenase-2 expression in fibroblasts, suggesting feedback loops that may influence its own production. Nitric oxide production is also controlled by TGF-beta1, revealing another layer of regulatory crosstalk.
negative regulation of transforming growth factor beta1 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GPR81 | Liver fibrosis | Knockout mouse; overexpression in hepatic stellate cells |
| Smad7 | Liver fibrosis; gut inflammation | Knock-in of Smad7; CRISPR activation |
| miR-204-5p | Asthma airway remodeling | Overexpression in airway smooth muscle cells |
| FOXA1 | Gallbladder carcinoma metastasis | Knockout in cancer cell lines; m6A modification studies |
| Metrnl/IL-41 | Asthma airway remodeling | Knockout mouse; recombinant protein treatment |
Liver fibrosis
Liver fibrosis is characterized by excessive extracellular matrix deposition driven by TGF-beta1. Deletion of GPR81 activates the CREB/Smad7 pathway, which negatively regulates TGF-beta1 signaling and alleviates liver fibrosis in mice. This demonstrates that enhancing negative regulation of TGF-beta1 production or signaling can be therapeutic. Smad7 induction is a key mechanism, and targeting GPR81 may offer a novel strategy for fibrosis treatment.
Gut inflammation and inflammatory bowel disease
In gut inflammation, a failure of TGF-beta1 negative regulation maintains sustained NF-kappaB activation, contributing to chronic inflammatory pathology. This suggests that restoring negative regulation of TGF-beta1 production could help resolve inflammation. The interplay between TGF-beta1 and NF-kappaB is a critical node in inflammatory bowel disease pathogenesis.
Asthma and airway remodeling
In asthma, TGF-beta1 promotes airway smooth muscle cell proliferation and extracellular matrix production, leading to airway remodeling. MiR-204-5p inhibits TGF-beta1-induced proliferation and ECM production by regulating Six1 in airway smooth muscle cells. Additionally, inhibition of macrophage extracellular traps by Metrnl/IL-41 suppresses airway remodeling, a process involving TGF-beta1-related mechanisms. These findings highlight negative regulation of TGF-beta1 as a potential therapeutic target in asthma.
Cancer metastasis
TGF-beta1 facilitates gallbladder carcinoma metastasis by regulating FOXA1 translation efficiency through m6A modification. Negative regulation of TGF-beta1 production could therefore oppose metastatic spread. Understanding how TGF-beta1 production is restrained may reveal new targets for anti-metastatic therapy.
From negative regulation of transforming growth factor beta1 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase TGF-beta1 production? | CRISPR knockout in cell lines or primary cells |
| Does a specific point mutation in a regulator alter TGF-beta1 suppression? | CRISPR point mutation knock-in |
| Can overexpression of Smad7 reduce fibrosis? | CRISPR knock-in of Smad7 under a strong promoter or overexpression vector |
| How does a tagged regulator localize and interact? | Tagged knock-in (e.g., GFP or HA) |
| Which genes negatively regulate TGF-beta1 in a genome-wide screen? | CRISPR library screening |
| Does miR-204-5p mimic reduce TGF-beta1-induced ECM? | Overexpression of miR-204-5p in airway smooth muscle cells |
How to Study the negative regulation of transforming growth factor beta1 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | mRNA levels of TGF-beta1 and regulators | Identifying transcriptional changes in knockout or overexpression models |
| ELISA | Secreted TGF-beta1 protein | Quantifying production in supernatants or serum |
| Western blot | Protein levels of Smad7, CREB, etc. | Validating pathway activation |
| Proliferation assay | Cell growth | Assessing TGF-beta1-induced proliferation |
| ECM protein quantification | Fibronectin, collagen deposition | Evaluating fibrosis or airway remodeling |
| CRISPR library screening | Genes affecting TGF-beta1 production | Discovery of novel negative regulators |
| Bioinformatics pathway analysis | Enriched signaling pathways | Interpreting omics data |
Transcriptional profiling (RNA-seq)
RNA sequencing can quantify TGF-beta1 mRNA levels and identify transcriptional changes in negative regulators such as Smad7 or GPR81. In liver fibrosis models, RNA-seq of GPR81 knockout mice revealed activation of CREB/Smad7 pathway. In asthma, RNA-seq of airway smooth muscle cells treated with miR-204-5p mimics can reveal downstream targets like Six1.
Protein quantification (ELISA, Western blot)
ELISA for TGF-beta1 in cell culture supernatants or serum is a direct measure of production. Western blot can assess Smad7, CREB, and other regulators. For example, TGF-beta1 levels were measured in models of liver fibrosis and asthma.
Functional assays (proliferation, ECM production)
Proliferation assays and extracellular matrix protein quantification (e.g., fibronectin, collagen) measure the biological outcomes of TGF-beta1 activity. MiR-204-5p inhibits TGF-beta1-induced proliferation and ECM production in airway smooth muscle cells. In liver fibrosis, ECM deposition is assessed histologically.
CRISPR screening and bioinformatics
Genome-wide CRISPR knockout screens can identify genes whose loss increases TGF-beta1 production. Bioinformatics analysis of transcriptomic data can reveal pathways such as CREB/Smad7. These approaches are powerful for discovering novel negative regulators.
How CRISPR Can Be Used to Study GO:0032911 negative regulation of transforming growth factor beta1 production
Knockout
CRISPR knockout of candidate negative regulators such as GPR81 can determine whether their loss increases TGF-beta1 production and exacerbates fibrosis. In mice, deletion of GPR81 activates CREB/Smad7 and alleviates liver fibrosis, demonstrating the utility of knockout models. Knockout of miR-204-5p target Six1 can reveal its role in airway remodeling.
Point Mutation
CRISPR point mutation knock-in can model specific amino acid changes in regulators like Smad7 or GPR81 to dissect domain functions. For example, mutating phosphorylation sites in Smad7 may alter its ability to suppress TGF-beta1 signaling. Such models are valuable for understanding mechanistic details.
Knock-in
Knock-in of tagged versions of Smad7 or GPR81 allows visualization and interaction studies. Additionally, knock-in of a constitutively active CREB can test whether enhancing the CREB/Smad7 axis suppresses TGF-beta1 production and fibrosis. Knock-in of miR-204-5p target sites can validate microRNA regulation.
Overexpression
Overexpression of Smad7 or miR-204-5p can suppress TGF-beta1 production and its downstream effects. In airway smooth muscle cells, overexpression of miR-204-5p inhibits TGF-beta1-induced proliferation and ECM production. Overexpression of Metrnl/IL-41 suppresses airway remodeling in asthma models.
How EDITGENE Supports negative regulation of transforming growth factor beta1 production Research
Researchers studying negative regulation of transforming growth factor beta1 production-related genes often need to determine whether a candidate gene is causally involved in suppressing TGF-beta1 production or signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from knockout and point mutation to knock-in and overexpression models, as well as library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of transforming growth factor beta1 production research.
Frequently Asked Questions About negative regulation of transforming growth factor beta1 production
What is GO:0032911?
GO:0032911 is the Gene Ontology term for negative regulation of transforming growth factor beta1 production, describing any process that stops, prevents, or reduces the production of TGF-beta1.
What genes are involved in negative regulation of TGF-beta1 production?
Key genes include Smad7, GPR81, CREB, miR-204-5p, Six1, Metrnl/IL-41, and NF-kappaB, among others.
How does Smad7 negatively regulate TGF-beta1?
Smad7 is an inhibitory Smad induced by the GPR81-CREB pathway that suppresses TGF-beta1 signaling and alleviates liver fibrosis.
What diseases are linked to defective negative regulation of TGF-beta1?
Liver fibrosis, gut inflammation, asthma airway remodeling, and cancer metastasis are linked to dysregulation of this process.
Can CRISPR knockout help study TGF-beta1 negative regulation?
Yes, CRISPR knockout of genes like GPR81 can reveal whether their loss increases TGF-beta1 production and worsens fibrosis.
What is the role of miR-204-5p in TGF-beta1 regulation?
MiR-204-5p inhibits TGF-beta1-induced proliferation and extracellular matrix production in airway smooth muscle cells by regulating Six1.
How is TGF-beta1 production measured in the lab?
ELISA of cell supernatants or serum, Western blot, and RNA-seq are common methods to quantify TGF-beta1 production.
What is the GPR81-CREB-Smad7 pathway?
It is a signaling axis where GPR81 activation induces CREB, which upregulates Smad7 to negatively regulate TGF-beta1 and alleviate liver fibrosis.
Why is negative regulation of TGF-beta1 important in asthma?
It limits airway smooth muscle proliferation and extracellular matrix deposition, reducing airway remodeling.
How can EDITGENE help my research on TGF-beta1 negative regulation?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to study genes involved in this process.
Conclusion
GO:0032911, negative regulation of transforming growth factor beta1 production, is a critical biological process that restrains the production of a master cytokine involved in fibrosis, inflammation, and cancer. Key regulators such as Smad7, GPR81, and miR-204-5p have been experimentally linked to this process, and their dysregulation contributes to diseases including liver fibrosis, gut inflammation, asthma, and metastasis. Understanding the molecular mechanisms and disease relevance of this term provides a foundation for therapeutic development. EDITGENE offers comprehensive CRISPR services to accelerate research on this important regulatory pathway.
References
- 1. Matsuki K et al.. 2015. Transforming growth factor beta1 and aldosterone.. Curr Opin Nephrol Hypertens 24(2):139-44 PMID: 25587902
- 2. Monteleone G et al.. 2004. A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation.. J Biol Chem 279(6):3925-32 PMID: 14600158
- 3. Zhi Y et al.. 2024. Deletion of GPR81 activates CREB/Smad7 pathway and alleviates liver fibrosis in mice.. Mol Med 30(1):99 PMID: 38982366
- 4. Wu Z et al.. 2024. TGF-β1 facilitates gallbladder carcinoma metastasis by regulating FOXA1 translation efficiency through m(6)A modification.. Cell Death Dis 15(6):422 PMID: 38886389
- 5. Feng K et al.. 2025. Inhibition of macrophage extracellular traps by Metrnl/IL-41 suppresses airway remodeling in asthma.. Biochem Pharmacol 242(Pt 1):117288 PMID: 40885323
- 6. Matsumura T et al.. 2009. Regulation of transforming growth factor-beta-dependent cyclooxygenase-2 expression in fibroblasts.. J Biol Chem 284(51):35861-71 PMID: 19837676
- 7. Vodovotz Y. 1997. Control of nitric oxide production by transforming growth factor-beta1: mechanistic insights and potential relevance to human disease.. Nitric Oxide 1(1):3-17 PMID: 9701040
- 8. Yang Z et al.. 2020. MiR-204-5p Inhibits Transforming Growth Factor-β1-Induced Proliferation and Extracellular Matrix Production of Airway Smooth Muscle Cells by Regulating Six1 in Asthma.. Int Arch Allergy Immunol 181(4):239-248 PMID: 31955160
